OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Gerds on the VERIFY Trial Examining Rusfertide in Polycythemia Vera

September 27th 2022

Aaron T. Gerds, MD, MS, discusses the phase 3 VERIFY trial examining rusfertide in patients with polycythemia vera.

Dr. Popat on the Investigation of Lurbinectedin in Second-line SCLC

September 27th 2022

Sanjay Popat, MBBS, FRCP, PhD, discusses the investigation of lurbinectedin as a second-line treatment for patients with small cell lung cancer.

Dr. Orellana-Noia on the Treatment of High-Risk and Vulnerable Patient Populations with DLBCL

September 26th 2022

Victor M. Orellana-Noia, MD, discusses the treatment of high-risk and vulnerable patients with diffuse large B-cell lymphoma.

Dr. Barata on the Evolving Treatment Landscape in Urothelial Cancer

September 26th 2022

Pedro C. Barata, MD, MSc, discusses the evolving treatment landscape of urothelial cancer.

Dr. Verstovsek on the Potential Role of Rusfertide in Polycythemia Vera

September 26th 2022

Srdan Verstovsek, MD, PhD, discusses the potential for rusfertide in polycythemia vera.

Dr. Girard on Examining the Real-World Effectiveness of Lurbinectedin in SCLC

September 26th 2022

Nicolas Girard, MD, PhD, discusses the investigation of lurbinectedin in small cell lung cancer.

Dr. Mascarenhas on the Investigation of Pelabresib in Myelofibrosis

September 23rd 2022

John O. Mascarenhas, MD, discusses the investigation of pelabresib in myelofibrosis.

Dr. Aragon-Ching on the Evolving Standard of Care with JAVELIN Bladder 100 in Urothelial Carcinoma

September 23rd 2022

Jeanny B. Aragon-Ching, MD, FACP, discusses the evolving standard of care based on findings from the phase 3 JAVELIN Bladder 100 trial in urothelial carcinoma.

Dr. Orellana-Noia on the Patient Population of the POLARIX Trial in DLBCL

September 23rd 2022

Victor M. Orellana-Noia, MD, discusses the patient population of the phase 3 POLARIX trial in diffuse large B-cell lymphoma.

Dr. Moon on the Future of Care in Prostate Cancer

September 21st 2022

Helen Heng-Shan Moon, MD, discusses the future of care in prostate cancer.

Dr. Aragon-Ching on the Implications of the JAVELIN Bladder 100 Trial in Urothelial Carcinoma

September 21st 2022

Jeanny B. Aragon-Ching, MD, FACP, discusses the clinical implications of the phase 3 JAVELIN Bladder 100 trial in urothelial carcinoma.

Dr. Matasar on the Unmet Needs of Immunotherapy for DLBCL

September 21st 2022

Matthew J. Matasar, MD, discusses the unmet needs remaining in diffuse large B-cell lymphoma.

Dr. Llanos on Genetic Disparities in Cancer Care

September 21st 2022

Adana A.M. Llanos, PhD, MPH, discusses disparities in genetic research in cancer care.

Dr. Goetz on the ELAINE-1 Trial of Lasofoxifene in ESR1-Mutated, ER+/HER2- Breast Cancer

September 19th 2022

Matthew P. Goetz, MD, discusses the progression-free survival benefit derived with lasofoxifene in patients with ESR1-mutated, ER-positive/ HER2-negative metastatic breast cancer.

Dr. Damodaran on the ELAINE-2 Trial of Lasofoxifene/Abemaciclib in ESR1-Mutated, ER+/HER2- Breast Cancer

September 19th 2022

Senthil Damodaran, MD, PhD, discusses data from the phase 2 ELAINE-2 trial examining the combination of lasofoxifene and abemaciclib in patients with ESR1-mutated, estrogen receptor–positive/HER2-negative metastatic breast cancer.

Dr. Gutierrez on the Investigation of MK-0482 in Advanced Solid Tumors

September 16th 2022

Martin E. Gutierrez, MD, discusses the investigation of MK-0482 in advanced solid tumors.

Dr. Bhatt on the Investigation of Trastuzumab Deruxtecan in HER2-Low Breast Cancer

September 16th 2022

Ruchi Bhatt, DO, discusses the investigation of trastuzumab deruxtecan in HER2-low breast cancer.

Dr. Anne on the Practice-Changing Data of DESTINY-Breast04 in HER2-Low Breast Cancer

September 16th 2022

Madhurima Anne, MD, discusses the practice-changing data of the phase 3 DESTINY-Breast04 trial in patients with HER2-low breast cancer.

Dr. Goy on Updates in Precision Medicine in Hematologic Malignancies

September 15th 2022

Andre H. Goy, MD, discusses updates in precision medicine.

Dr. Ip on the Utility of Carboplatin, Pemetrexed, and Pembrolizumab in Lung Adenocarcinoma

September 15th 2022

Andrew Ip, MD, discusses carboplatin, pemetrexed, and pembrolizumab as first-line therapy in recurrent/metastatic non–small cell lung cancer.